Veracyte | VCYT - Gross Profit On Sales


Veracyte reported $101.16M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Agenus USD 34.2M 4.61M Dec/2025
Agilent USD 990M 44M Mar/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Bruker USD 379.8M 69.4M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Illumina USD 721M 38M Mar/2026
Intrexon USD -297K 167K Jun/2024
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Laboratory Of America USD 1.01B 20.6M Mar/2026
Ligand Pharmaceuticals USD 48.45M 8.22M Mar/2026
Myriad Genetics USD 146.8M 3M Dec/2025
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Siemens EUR 7.63B 471M Dec/2025
Sonic Healthcare AUD 3.92B 3.14B Dec/2024
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Veracyte USD 101.16M 814K Mar/2026
Waters USD 542M 15.42M Mar/2026